Comparison of 129Xe MRI With 19F MRI in CF Lung Disease

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

May 29, 2018

Primary Completion Date

April 9, 2019

Study Completion Date

April 10, 2019

Conditions
Cystic Fibrosis
Interventions
DRUG

Hyperpolarized Xenon gas

"Hyperpolarized Xenon gas~* Hyperpolarized mixture (750ml HP 129Xe and 250ml nitrogen)~* Administration: By mouthpiece attached to a single use Tedlar bag.~* Dosage: 750 mL of the 129Xe mixture up to, but not exceeding, four doses of the 129Xe.~* Frequency: 10-minute interval between doses."

DRUG

PFP

"* Inhaled PFP, a gaseous contrast agent (79% PFP; 21% O2, pre-mixed, medical grade gas)~* Administration: Full-face disposable ventilation mask and a standard Douglas Bag system.~* Dosage: Two controlled breaths of the contrast gas followed by a full breath and a 12-second breath-hold and scan for image acquisition.~* Frequency: Repeated 5 times followed by an identical five cycles with room air to ensure PFP gas wash-out has occurred."

Trial Locations (1)

27599

The University of North Carolina at Chapel Hill, Chapel Hill

All Listed Sponsors
collaborator

Cystic Fibrosis Foundation

OTHER

lead

University of North Carolina, Chapel Hill

OTHER

NCT03482960 - Comparison of 129Xe MRI With 19F MRI in CF Lung Disease | Biotech Hunter | Biotech Hunter